Announcements Trials
Browse Landscape

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 1Breast Diseases 1Breast Carcinoma In Situ 1

Interventions

Fulvestrant 81Letrozole 74Paclitaxel 71pembrolizumab 67Specimen Handling 63Trastuzumab 60Carboplatin 55Magnetic Resonance Spectroscopy 50ribociclib 47Capecitabine 47Anastrozole 45palbociclib 44pertuzumab 43Tamoxifen 38Cyclophosphamide 38exemestane 37abemaciclib 37Biopsy 35trastuzumab deruxtecan 30Docetaxel 28Taxes 27Gemcitabine 25Radiotherapy 24Surveys and Questionnaires 23130-nm albumin-bound paclitaxel 23Standard of Care 21Blood Specimen Collection 21sacituzumab govitecan 20olaparib 20eribulin 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Genotype × Breast × 90 days × Clear all
NCT05006196 2026-05-20

IMOGEN

Perspectum

Active not recruiting
1,030 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT05755269 2026-05-01

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

Mayo Clinic

Terminated
19 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡